TWO EXPERIMENTAL drugs, members of a new class of agents that target a key enzyme required by influenza viruses, show promise as the most potent medications developed to date for treating the infection.
Results from studies recently reported at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) indicate that the new agents reduce the duration and severity of influenza in otherwise-healthy adults, including high-risk individuals such as the elderly. The new studies also found that the drugs, when given prophylactically, offered significant protection against infection during an outbreak of influenza.
Stephenson J. Progress Treating, Preventing Influenza. JAMA. 1998;280(20):1729-1730. doi:10.1001/jama.280.20.1729